Lefler, Sharon
Ben-Shachar, Berta
Masasa, Hila
Schreiber, David
Tamir, Idan
Article History
Received: 15 October 2021
Revised: 20 December 2021
Accepted: 18 January 2022
First Online: 1 February 2022
Declarations
:
: All authors are employees of QuLab Medical, which has filed for three patent applications that cover its core technology:ELECTROCHEMICAL FET SENSOR 62/873,440 – national phase. Priority date – 12-Jul-2019 – this application protects our innovative SiNW-FET-based electrochemical sensor technology, including specific features, such as enhanced sensitivity, reduction of interfering substances noise, and sensor design considerations.SENSING SYSTEM INCLUDING LAYERED MICROPROBE 62/962,677 – national phase. Priority date – 17-Jan-2020 – this application protects the concept of laminating ceramic material-based sensors (e.g., SiNW-FET) with a metallic support to prevent sensor fracture and improve tissue penetration for effective metabolite monitoring.MINIMALLY INVASIVE CONTINUOUS METABOLIC MONITORING PATCH DESIGN 63/060,361 – PCT. Priority date – 03-Aug-2020 – this application protects our applicator-free patch design and its key mechanical components.